The experimental drug ERAS-0015 has demonstrated clinical safety and tumor reduction in patients with advanced pancreatic and lung cancers, according to results from the phase I AURORAS-1 clinical trial.
Presented this week at the 38th EORTC-NCI-AACR Symposium in Barcelona, the study highlights the drug’s potential to target previously “undruggable” RAS gene mutations, according to ConSalud. Results presented correspond to 83 patients with pancreatic cancer and 37 with non-small cell lung cancer; the trial continues recruiting patients. Combating tumors driven by alterations in the RAS gene has been considered an almost impossible mission within medicine.
Clinical Insights for Patients
- Targeted Action: ERAS-0015 acts as a “pan-RAS molecular glue,” binding to mutated proteins to switch off the signals that force cancer cells to multiply. ERAS-0015 belongs to a new class of drugs called “pan-RAS molecular glue.” Its mechanism consists of binding proteins at the molecular level to block tumor growth signals originating from distinct RAS mutations. Certain RAS mutations function as a switch stuck in the “on” position, continuously transmitting signals that originate and perpetuate cancer.
- Treatment Efficacy: Among participants with limited therapeutic options, the drug induced tumor shrinkage in 44% of pancreatic cancer cases and 60% of lung cancer cases at a 32 mg dosage. Tumor reduction was observed in 11 of 25 patients (44%) with pancreatic cancer who received 32 mg and had previously been treated with chemotherapy. In the case of lung cancer, three of five patients (60%) treated with the same dose recorded tumor reduction; these participants had previously received an immune checkpoint inhibitor or platinum-based chemotherapy.
- Current Status: The trial is ongoing, meaning full regulatory approval remains pending further phase II and III studies to confirm long-term safety and efficacy. New studies with a larger number of patients, as well as phase II and III clinical trials, will be necessary to confirm both the safety and efficacy of ERAS-0015.
AURORAS-1 Trial Design and RAS Mutation Targeting
The AURORAS-1 study, which began in June 2025, investigates ERAS-0015 as both a monotherapy and in combination with existing cancer treatments. infosalus reported that the trial includes 148 patients suffering from solid tumors, such as non-small cell lung cancer (NSCLC) and pancreatic cancer, characterized by mutations in the RAS gene.
These mutations act as a cellular “on-switch,” driving continuous, uncontrolled tumor growth. The data disclosed focus on 83 people with pancreatic cancer and 37 with lung cancer who had already gone through previous treatments without success, such as chemotherapy or immunotherapy. Included patients have locally advanced or metastatic non-small cell lung cancer, pancreatic cancer, colorectal cancer, or other solid tumors.
Dr. Judy Wang, a medical oncologist at the Florida Cancer Specialists and Research Institute, emphasized that the drug targets the “Achilles’ heel” of these specific cancers, according to infosalus. “In the AURORAS-1 study, we included patients who had tried various treatments for their cancer,” Dr. Wang told infosalus. As the doctor explained, the goal of precision oncology is to attack directly the “Achilles’ heel” of each person’s tumor.
“The overall goal of precision oncology is to find a drug that acts directly on a patient’s mutation, or the ‘Achilles’ heel’ of their cancer. This is what we are trying to achieve by studying the efficacy of ERAS-0015 in patients with RAS gene alterations,” said Dr. Wang.
By focusing on the molecular structure of the mutated protein, the drug aims to block growth signals that have historically resisted conventional pharmacological intervention.

ERAS-0015 Shows Favorable Safety up to 40 Mg Dose
Data from the trial indicate that the drug remains well-tolerated at dosages ranging from 2 mg to 40 mg. The study has not yet reached the maximum tolerated dose, suggesting a favorable safety profile thus far. Doses of ERAS-0015 started at 2 mg and increased up to 40 mg.
During a median follow-up period of just over four months, there were no indications that the maximum tolerated dose had been reached. According to ConSalud, adverse effects such as skin rashes, nausea, diarrhea, and oral mucositis (inflammation of the mouth lining) occurred in at least 10% of participants receiving 16 to 32 mg doses.
| Cancer Type | Response Rate | Patients (N) |
|---|---|---|
| Pancreatic Cancer | 44% | 11 of 25 |
| Non-Small Cell Lung Cancer | 60% | 3 of 5 |
IM Médico reported that only 9.8% of patients experienced grade 3 or higher adverse events related to the treatment. No adverse event limited drug doses. Investigators said that none of these side effects were severe enough to require a reduction or cessation of the dosage, marking a significant milestone for patients who had previously exhausted standard chemotherapy or immunotherapy options.
“We are encouraged by the preliminary clinical activity and tolerability of ERAS-0015 in patients who have already tried several treatments against RAS-driven lung and pancreatic cancers,” said Dr. Wang.
As this is a phase I trial, ERAS-0015 is not yet available for general clinical use and is reserved strictly for participants meeting specific trial inclusion criteria.
“Si estos resultados preliminares se confirman, el medicamento podría convertirse en una nueva alternativa para las personas con tumores impulsados por mutaciones RAS”, ha señalado Wang. “This is one of several studies being presented at the EORTC-NCI-AACR Symposium that are beginning to demonstrate that it is possible to design drugs targeting cancers driven by RAS mutations, something that until recently was considered impossible,” concluded Garralda.
Related reading
- PSA Screening Reduces Prostate Cancer Deaths but Increases Overdiagnosis: Cochrane Review
- Nelson Type 1 Diabetes Support Group Fills Care Gap for Adults
- Woman Loses Father, Mother and Sister to Same Aggressive Brain Cancer (archynewsy.com)
- Pope Leo XIV Cleared for South America Tour After Lung Cancer Surgery (newsdirectory3.com)